Anti-GFRAL antibody

Target data

Brainstem-restricted receptor for GDF15 hormone, which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses (PubMed : 28846097, PubMed : 28846098, PubMed : 28846099, PubMed : 28953886, PubMed : 31152154, PubMed : 31928886, PubMed : 32723474, PubMed : 33593916, PubMed : 35202387, PubMed : 36630958, PubMed : 37380764). The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future (PubMed : 28846097, PubMed : 28846098, PubMed : 28846099, PubMed : 28953886, PubMed : 31928886, PubMed : 32723474, PubMed : 33593916, PubMed : 35202387, PubMed : 36630958). The GDF15-GFRAL aversive response is triggered by stresses, such as anticancer drugs (camptothecin or cisplatin), cancers or drugs such as metformin (PubMed : 31875646, PubMed : 31928886, PubMed : 32661391, PubMed : 32723474). Upon interaction with its ligand, GDF15, mediates the GDF15-induced autophosphorylation and activation of the RET tyrosine kinase receptor, leading to activation of MAPK- and AKT- signaling pathways (PubMed : 28846098, PubMed : 28846099, PubMed : 32723474, PubMed : 33593916). Ligand-binding activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem (PubMed : 28846098, PubMed : 28846099, PubMed : 31152154, PubMed : 32723474). The GDF15-GFRAL signal induces expression of genes involved in metabolism, such as lipid metabolism in adipose tissues (PubMed : 32661391).